Physician group Cellular Medicine Association stated on Monday that the US FDA has approved the use of the plasma (convalescent plasma) from the survivors of COVID-19 to be given as a life-saving treatment to those who may still be fighting to survive acute COVID-19 infection.
Cellular Medicine Association said people who survive COVID-19 harbor antibodies in their blood that fought the virus and won. Physicians struggle to quickly find the blood of a local person who has survived COVID-19 and who can donate the life-saving convalescent plasma, but the survivors do not know where to go to donate their blood.
The organisation has built a website, COVID19Switchboard.org, that connects those looking for blood and those wanting to give blood. This free switchboard works in every country (using Google Translate).
About 2000 company physicians and nurse practitioners in over 50 countries focus on connect potential donors with physicians through the procedures invented by Dr Runels--the Vampire Facelift, the Vampire Facial, the O-Shot and the Priapus Shot.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial